Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization precipitation generation technology for rainfall and snowpack enhancement. Its updates center on the Weather Enhancement Technology Array (WETA), U.S. installations, weather-modification permits, independent analyses of agricultural water benefits, and reported precipitation results in mountain and arid environments.
The company also reports research into adjacent atmospheric applications, including fog mitigation and air pollution or smog mitigation. Governance updates and commercialization milestones appear alongside technical disclosures about its chemical-free, solar-powered ionization approach.
Rain Enhancement Technologies Holdco (RAIN) has announced the appointment of Randy Seidl as Chief Executive Officer, transitioning from his previous role as Co-CEO since January 2, 2025. Seidl brings over 30 years of technology industry experience, having served in executive positions at Hewlett Packard, Sun Microsystems, and EMC
Chris Riley has stepped down as Co-CEO but will remain on the Company's Board. Seidl, who holds a degree from Boston College's Carroll School of Management and serves on multiple corporate boards including Ondas Holdings, will focus on developing and commercializing RET's ionization rainfall generation technology across various sectors including energy, agriculture, logistics, transportation, and decarbonization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Rain Oncology Inc. (NASDAQ: RAIN) announced that it will report its first quarter financial results for the period ending March 31, 2023, along with updates on its business on May 11, 2023. The company is focused on developing precision oncology therapeutics, particularly its lead candidate, milademetan, which inhibits the MDM2-p53 complex to reactivate p53. A conference call and webcast will follow the earnings release, scheduled for 2:00 PM PT (5:00 PM ET) on the same day. Investors can access the call via phone or through the provided webcast link. Rain's strategy involves a tumor-agnostic approach, selecting patients based on tumor genetics.